Get started
Work

Supplementary Tables from Pralatrexate in Combination with Oxaliplatin in Advanced Esophagogastric Cancer: A Phase II Trial with Predictive Molecular Correlates

Year: 2023
Type: supplementary-materials
Abstract: Supplementary Table S1 is summarizing grade 3 or higher adverse events Supplementary Table S2 is listing the most common adverse events Supplementary Table S3 is summarizing the distribution of genotype and allele frequencies in patients Supplementary Table S4 is comparing between patients with a median overall survival of greater or less than 10 months, the historic median survival in this population Supplementary Table S5 is showing the median number of chemotherapy cycles by SNPs
DOI: 10.1158/1535-7163.22506625.v1
Authors: Usha Malhotra, Sarbajit Mukherjee, Christos Fountzilas, Patrick Boland, Austin Miller, Santosh Patnaik, Kristopher Attwood, Sai Yendamuri, Araba Adjei, Eric Kannisto, Mateusz Opyrchal, Peter Bushunow, Peter Loud, Renuka Iyer, Nikhil Khushalani
Language: English
Field: Medicine
Open Access status: gold
OpenAlex ID: W4362534907
Cites:
Cited by:
Related to: 10